Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (20)

2024

  1. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

2023

  1. Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer

    Cancers, Vol. 15, Núm. 5

  2. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  3. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

  4. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

  5. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

    Cell Reports Medicine, Vol. 4, Núm. 11

2022

  1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  2. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

  3. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178

2021

  1. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

    ESMO open, Vol. 6, Núm. 3, pp. 100113

  2. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969

2020

  1. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740

2017

  1. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer

    Clinical Lung Cancer

  2. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

  3. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

    Lung Cancer, Vol. 112, pp. 181-187

2015

  1. A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

    Clinical Cancer Research, Vol. 21, Núm. 4, pp. 730-738

2013

  1. Epidermal growth factor receptor inhibition in lung cancer: Status 2012

    Journal of Thoracic Oncology, Vol. 8, Núm. 3, pp. 373-384

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

  1. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

    British Journal of Cancer, Vol. 104, Núm. 1, pp. 68-74

2010

  1. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition

    Clinical Cancer Research, Vol. 16, Núm. 18, pp. 4654-4665